8-K: Spruce Biosciences Halts Tildacerfont Development After Phase 2b Trial Fails to Meet Primary Endpoint

Spruce Biosciences announced that its Phase 2b trial for tildacerfont in adult Congenital Adrenal Hyperplasia (CAH) did not meet its primary endpoint, leading to the discontinuation of the program.

Summary

• Spruce Biosciences has released topline results from its CAHmelia-204 and CAHptain-205 studies of tildacerfont for Congenital Adrenal Hyperplasia (CAH).
• The CAHmelia-204 study, a Phase 2b trial in adults with CAH, did not meet its primary endpoint of reducing daily glucocorticoid (GC) dose at week 24.
• The study involved 100 adults with classic CAH, who were on a mean GC dose of 35mg/day of hydrocortisone equivalents (HCe) and had a mean androstenedione (A4) level of 214 ng/dL at baseline.
• The 200mg once-daily dose of tildacerfont showed a placebo-adjusted reduction of 0.7mg HCe, which was not statistically significant (p=0.7).
• The CAHptain-205 study, a Phase 2 open-label trial, evaluated different doses of tildacerfont in adult and pediatric CAH patients.
• This study observed a trend of larger reductions in A4 levels with higher twice-daily doses of tildacerfont.
• Both studies reported that tildacerfont was generally safe and well-tolerated with no serious adverse events.
• Spruce Biosciences will discontinue both the CAHmelia-204 and CAHptain-205 clinical trials and wind down its investment in tildacerfont for CAH.
• The company plans to evaluate a full range of strategic options to address diseases with serious unmet needs.

Sentiment

Score: 3

Explanation: The document reports a significant setback with the failure of a key clinical trial and the subsequent discontinuation of the program, leading to a negative sentiment.

Positives

• Tildacerfont was generally safe and well-tolerated in both studies, with no serious adverse events reported.
• The CAHptain-205 study showed a trend of larger reductions in A4 levels with higher twice-daily doses of tildacerfont.
• Approximately 98% of patients in the CAHmelia-204 study were highly compliant with the study drug.

Negatives

• The CAHmelia-204 study failed to meet its primary efficacy endpoint of reducing daily GC dose.
• The placebo-adjusted reduction in daily GC dose was not statistically significant.
• Spruce Biosciences will discontinue the tildacerfont program for CAH, indicating a setback in their development pipeline.

Risks

• The failure of the Phase 2b trial may negatively impact investor confidence in Spruce Biosciences.
• Discontinuing the tildacerfont program will require the company to re-evaluate its strategic direction.
• The company faces the risk of not finding a suitable alternative program to replace the tildacerfont program.

Future Outlook

Spruce Biosciences plans to evaluate a full range of strategic options to address diseases with serious unmet needs, following the discontinuation of the tildacerfont program.

Management Comments

• The company plans to evaluate a full range of strategic options in addressing diseases with serious unmet need for patients.
• The CAHmelia-204 and CAHptain-205 clinical trials will be discontinued, and the Company will be winding down its investment in tildacerfont for the treatment of CAH.

Industry Context

The failure of the tildacerfont trial highlights the challenges in developing effective treatments for rare diseases like CAH. This outcome may lead to increased scrutiny of other companies pursuing similar therapeutic approaches.

Comparison to Industry Standards

• The failure of the primary endpoint in the CAHmelia-204 trial is a setback compared to other successful Phase 2b trials in similar therapeutic areas.
• Other companies developing treatments for CAH, such as Crinetics Pharmaceuticals with their CRN04808, have shown more promising results in reducing androgen levels and GC usage.
• The discontinuation of the tildacerfont program contrasts with the ongoing development of other CAH therapies, indicating a potential competitive disadvantage for Spruce Biosciences in this specific market.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failure of the clinical trial and discontinuation of the program.
• Employees involved in the tildacerfont program may be affected by the wind-down of the investment.
• Patients with CAH may be disappointed by the discontinuation of a potential treatment option.

Next Steps

• Spruce Biosciences will evaluate a full range of strategic options.
• The company will discontinue the CAHmelia-204 and CAHptain-205 clinical trials.
• The company will wind down its investment in tildacerfont for the treatment of CAH.

Key Dates

Keywords

tildacerfont, Congenital Adrenal Hyperplasia, CAH, clinical trial, Phase 2b, glucocorticoid, androstenedione, drug development, Spruce Biosciences, pharmaceutical